Daniel Hayes caught the biomarker bug in 1986, when he helped to identify CA15-3 as a marker for breast cancer. Despite initial hopes that biomarkers would revolutionize patient care, three decades on he is disappointed with the pace of progress. Working with colleagues, he recently outlined the “vicious cycle” that is keeping biomarkers down. Hayes, a medical oncologist based at the University of Michigan, USA, tells Asher Mullard that the only way to break the cycle is simultaneous action on biomarker regulation, reimbursement, investment, peer review and usage guideline development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Macroscopic Stiffness of Breast Tumors Predicts Metastasis
Scientific Reports Open Access 01 July 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Daniel Hayes. Nat Rev Drug Discov 12, 734–735 (2013). https://doi.org/10.1038/nrd4137
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4137
This article is cited by
-
Macroscopic Stiffness of Breast Tumors Predicts Metastasis
Scientific Reports (2014)
